Senem Arda Düz1,2, Akın Mumcu1,3, Berat Doğan1,4, Ercan Yılmaz2, Ebru İnci Çoşkun2, Erdinç Sarıdogan1,2, Görkem Tuncay1,2, Abdullah Karaer5,6. 1. Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Turkey. 2. Department of Obstetrics and Gynecology, School of Medicine, Inonu University, 44315, Malatya, Turkey. 3. Laboratory of NMR, Scientific and Technological Research Center, Inonu University, Malatya, Turkey. 4. Department of Biomedical Engineering, School of Engineering, Inonu University, Malatya, Turkey. 5. Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Turkey. drkaraer@yahoo.com. 6. Department of Obstetrics and Gynecology, School of Medicine, Inonu University, 44315, Malatya, Turkey. drkaraer@yahoo.com.
Abstract
PURPOSE: To analyze endometrial metabolite profiles between patients with endometrial cancer and controls. METHODS: Seventeen (17) women with endometrium cancer and 18 controls were enrolled in this study. 1H HR-MAS (High Resolution-Magic Angle Spinning) NMR (Nuclear Magnetic Resonance) spectroscopy data obtained from endometrial tissue samples of patients with endometrial cancer and control group were analyzed with bioinformatics methods. RESULTS: Principal component analysis (PCA) and the partial least squares discriminant analysis (PLS-DA) score plots obtained with the multivariate statistical analysis of pre-processed spectral data shows a separation between the samples from patients with endometrial cancer and controls. Analysis results suggest that the levels of lactate, glucose, o-phosphoethanolamine, choline, glycerophosphocholine, phosphocholine, leucine, isoleucine, valine, glutamate, glutamine, n-acetyltyrosine, methionine, taurine, alanine, aspartate and phenylalanine are increased in patients with endometrial cancer compared to the controls. CONCLUSION: The metabolomics signature of patients with endometrial cancer is different from that of benign endometrial tissue.
PURPOSE: To analyze endometrial metabolite profiles between patients with endometrial cancer and controls. METHODS: Seventeen (17) women with endometrium cancer and 18 controls were enrolled in this study. 1H HR-MAS (High Resolution-Magic Angle Spinning) NMR (Nuclear Magnetic Resonance) spectroscopy data obtained from endometrial tissue samples of patients with endometrial cancer and control group were analyzed with bioinformatics methods. RESULTS: Principal component analysis (PCA) and the partial least squares discriminant analysis (PLS-DA) score plots obtained with the multivariate statistical analysis of pre-processed spectral data shows a separation between the samples from patients with endometrial cancer and controls. Analysis results suggest that the levels of lactate, glucose, o-phosphoethanolamine, choline, glycerophosphocholine, phosphocholine, leucine, isoleucine, valine, glutamate, glutamine, n-acetyltyrosine, methionine, taurine, alanine, aspartate and phenylalanine are increased in patients with endometrial cancer compared to the controls. CONCLUSION: The metabolomics signature of patients with endometrial cancer is different from that of benign endometrial tissue.
Authors: Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz Journal: Arch Med Sci Date: 2010-12-29 Impact factor: 3.318
Authors: J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396